Updates to HER2 testing guidelines reduces confusion
Drug Discovery World
JUNE 14, 2023
After reviewing results of the DESTINY-Breast04 trial and other studies, the CAP/ASCO panel determined that the current HER2 testing recommendations remain valid to identify all breast cancer patients who might benefit from the full spectrum of HER2 related therapies.
Let's personalize your content